Rocket Pharmaceuticals, Inc. Income Tax Expense
Rocket Pharmaceuticals, Inc. (RCKT) reported Income Tax Expense of $8.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was $8.62M.
- Rocket Pharmaceuticals, Inc. income tax expense (benefit) for the quarter ending 2025-06-30 was $0.00.
- Rocket Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2025 was $0.00.
- Rocket Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
- Rocket Pharmaceuticals, Inc. income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2026-06-30 | $8.62M 10-Q · filed 2026-08-10 | $8.62M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |